Some major healthcare companies, including DaVita, Cigna, Encompass, CVS Health and Walmart, are sending back federal aid funding they received that was intended to help hospitals and healthcare providers during the COVID-19 pandemic.
More than 1,750 standalone Medicare Part D prescription drug plans and MA plans have applied to offer insulin at a maximum $35 copay for a month’s supply of the drug for the 2021 plan year, CMS announced.
The healthcare sector has seen an influx of funding from private equity groups over the last several years, aiding in the contraction of the industry. But has the influence of cash been beneficial for healthcare?
While emerging conventional wisdom may state biopharmaceutical companies could see a boon as a result of the COVID-19 pandemic thanks to new treatment and vaccine opportunities, the sector may not come out on top.
Testing all residents and staff at the nation’s nursing homes just once would collectively cost $440 million, according to data from the American Health Care Association and National Center of Assisted Living (AHCA/NCAL).
Hospitals and healthcare providers are facing higher costs to care for complex COVID-19 patients while also suffering the loss of other procedures like elective surgeries that could help offset these higher costs.